REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Hyd Kutato-Fejleszto Kft. (Hungary)

Main Activities: Research and Development in the Physical, Engineering, and Life Sciences
Full name: HYD Rakkutato Es Gyogyszerfejleszto Kft. Profile Updated: July 26, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Hungarian Download a sample report

HYD LLC. for Cancer Research and Drug Development is a cancer research and pharmaceutical development company. The company specializes in sterile distilled water with 25 ppm deuterium content for research purposes. Their focus is on anti-cancer solutions and a new pharmaceutical development strategy based on deuterium depletion. They also aim to prove the therapeutic effectiveness of deuterium depletion in the veterinary field.

Headquarters
Villanyi ut 97.
Budapest; Budapest; Postal Code: 1118

Contact Details: Purchase the Hyd Kutato-Fejleszto Kft. report to view the information.

Website: http://www.hyd.hu

Basic Information
Total Employees:
Purchase the Hyd Kutato-Fejleszto Kft. report to view the information.
Outstanding Shares:
Purchase the Hyd Kutato-Fejleszto Kft. report to view the information.
Registered Capital:
Purchase the Hyd Kutato-Fejleszto Kft. report to view the information.
Financial Auditors:
Purchase the Hyd Kutato-Fejleszto Kft. report to view the information.
Incorporation Date:
November 01, 1992
Key Executives
Purchase this report to view the information.
Managing Director
Ownership Details
Purchase this report to view the information.
Subsidiaries
HYD Laboratory Kft.
Company Performance
Financial values in the chart are available after Hyd Kutato-Fejleszto Kft. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency HUF. Absolute financial data is included in the purchased report.
Net sales revenue
14.79%▲
Total operating revenue
13.95%▲
Operating profit (EBIT)
40.37%▲
EBITDA
30.46%▲
Net Profit (Loss) for the Period
118.12%▲
Total assets
12.49%▲
Total equity
73.4%▲
Operating Profit Margin (ROS)
1.07%▲
Net Profit Margin
2.69%▲
Return on Equity (ROE)
2.41%▲
Quick Ratio
-0.01%▼
Cash Ratio
0.02%▲

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo